Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases

Virginia Solitano; Ferdinando D'Amico; Carmen Correale; Laurent Peyrin-Biroulet; Silvio Danese

doi:10.1093/bmb/ldaa033

Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases

Virginia Solitano, Ferdinando D'Amico, Carmen Correale, Laurent Peyrin-Biroulet, Silvio Danese

Istituto Clinico Humanitas

Research output: Contribution to journal › Article › peer-review

Abstract

INTRODUCTION: Several studies have shown that inflammatory bowel diseases (IBD) patients treated with thiopurines have an increased risk of developing skin cancer.

SOURCES OF DATA: This review is based on recent published literature regarding the use of thiopurines in IBD and skin malignancies.

AREAS OF AGREEMENT: Exposure to thiopurines is significantly associated with nonmelanoma skin cancer, but not with melanoma. Primary and secondary prevention including sun-protective measures and regular dermatologic screening are recommended in IBD patients, particularly in those exposed to thiopurines.

AREAS OF CONTROVERSY: Both when and how immunosuppressive therapy should be resumed in patients with a prior history of skin cancer still remain debatable topics.

GROWING POINTS: The benefit-risk balance between thiopurine therapy and risk of skin cancer should be evaluated in the drug decision process.

AREAS TIMELY FOR DEVELOPING RESEARCH: The approval of new effective strategies requires the re-evaluation of the positioning of thiopurines within the therapeutic algorithm based on an increasingly individualized approach.

Original language	English
Pages (from-to)	107-117
Number of pages	11
Journal	British Medical Bulletin
Volume	136
Issue number	1
DOIs	https://doi.org/10.1093/bmb/ldaa033
Publication status	Published - Dec 15 2020

Access to Document

10.1093/bmb/ldaa033

Fingerprint Dive into the research topics of 'Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases'. Together they form a unique fingerprint.

Cite this

@article{ac98de11891e47118c2bf0d3590dcfb7,

title = "Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases",

abstract = "INTRODUCTION: Several studies have shown that inflammatory bowel diseases (IBD) patients treated with thiopurines have an increased risk of developing skin cancer.SOURCES OF DATA: This review is based on recent published literature regarding the use of thiopurines in IBD and skin malignancies.AREAS OF AGREEMENT: Exposure to thiopurines is significantly associated with nonmelanoma skin cancer, but not with melanoma. Primary and secondary prevention including sun-protective measures and regular dermatologic screening are recommended in IBD patients, particularly in those exposed to thiopurines.AREAS OF CONTROVERSY: Both when and how immunosuppressive therapy should be resumed in patients with a prior history of skin cancer still remain debatable topics.GROWING POINTS: The benefit-risk balance between thiopurine therapy and risk of skin cancer should be evaluated in the drug decision process.AREAS TIMELY FOR DEVELOPING RESEARCH: The approval of new effective strategies requires the re-evaluation of the positioning of thiopurines within the therapeutic algorithm based on an increasingly individualized approach.",

author = "Virginia Solitano and Ferdinando D'Amico and Carmen Correale and Laurent Peyrin-Biroulet and Silvio Danese",

year = "2020",

month = dec,

day = "15",

doi = "10.1093/bmb/ldaa033",

language = "English",

volume = "136",

pages = "107--117",

journal = "British Medical Bulletin",

issn = "0007-1420",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Thiopurines and non-melanoma skin cancer

T2 - partners in crime in inflammatory bowel diseases

AU - Solitano, Virginia

AU - D'Amico, Ferdinando

AU - Correale, Carmen

AU - Peyrin-Biroulet, Laurent

AU - Danese, Silvio

PY - 2020/12/15

Y1 - 2020/12/15

N2 - INTRODUCTION: Several studies have shown that inflammatory bowel diseases (IBD) patients treated with thiopurines have an increased risk of developing skin cancer.SOURCES OF DATA: This review is based on recent published literature regarding the use of thiopurines in IBD and skin malignancies.AREAS OF AGREEMENT: Exposure to thiopurines is significantly associated with nonmelanoma skin cancer, but not with melanoma. Primary and secondary prevention including sun-protective measures and regular dermatologic screening are recommended in IBD patients, particularly in those exposed to thiopurines.AREAS OF CONTROVERSY: Both when and how immunosuppressive therapy should be resumed in patients with a prior history of skin cancer still remain debatable topics.GROWING POINTS: The benefit-risk balance between thiopurine therapy and risk of skin cancer should be evaluated in the drug decision process.AREAS TIMELY FOR DEVELOPING RESEARCH: The approval of new effective strategies requires the re-evaluation of the positioning of thiopurines within the therapeutic algorithm based on an increasingly individualized approach.

AB - INTRODUCTION: Several studies have shown that inflammatory bowel diseases (IBD) patients treated with thiopurines have an increased risk of developing skin cancer.SOURCES OF DATA: This review is based on recent published literature regarding the use of thiopurines in IBD and skin malignancies.AREAS OF AGREEMENT: Exposure to thiopurines is significantly associated with nonmelanoma skin cancer, but not with melanoma. Primary and secondary prevention including sun-protective measures and regular dermatologic screening are recommended in IBD patients, particularly in those exposed to thiopurines.AREAS OF CONTROVERSY: Both when and how immunosuppressive therapy should be resumed in patients with a prior history of skin cancer still remain debatable topics.GROWING POINTS: The benefit-risk balance between thiopurine therapy and risk of skin cancer should be evaluated in the drug decision process.AREAS TIMELY FOR DEVELOPING RESEARCH: The approval of new effective strategies requires the re-evaluation of the positioning of thiopurines within the therapeutic algorithm based on an increasingly individualized approach.

U2 - 10.1093/bmb/ldaa033

DO - 10.1093/bmb/ldaa033

M3 - Article

C2 - 33200781

VL - 136

SP - 107

EP - 117

JO - British Medical Bulletin

JF - British Medical Bulletin

SN - 0007-1420

IS - 1

ER -